1-3 of 3
Serge Cremers
Close
Sort by
Journal Articles

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

Clinical Trials & Observations
Jennifer E. Amengual, Renee Lichtenstein, Jennifer Lue, Ahmed Sawas, Changchun Deng, Emily Lichtenstein, Karen Khan, Laine Atkins, Aishling Rada, Hye A. Kim, Codruta Chiuzan, Matko Kalac, Enrica Marchi, Lorenzo Falchi, Mark A. Francescone, Lawrence Schwartz, Serge Cremers, Owen A. O’Connor
Journal: Blood
Blood (2018) 131 (4): 397–407.
https://doi.org/10.1182/blood-2017-09-806737
Published: 2018
Includes: Supplemental data
Journal Articles

The Pralatrexate - Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Jennifer E Amengual, MD, Renee Lichtenstein, Celeste Rojas, Ahmed Sawas, MD, Changchun Deng, MD PhD, Emily Lichtenstien, Karen Kahn, Jennifer Kimberly Lue, MD, Yuxuan Liu, PhD, Changhong Qiao, Renu Nandakumar, PhD, Serge Cremers, PhD, Owen A. O'Connor, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1824.
https://doi.org/10.1182/blood.V128.22.1824.1824
Published: 2016
Journal Articles

Novel Imaging Modalities in Innovative Xenograft Mouse Models of T-Cell Lymphoma Confirm Marked Synergy of Romidepsin and Pralatrexate.

Salvia Jain, MD, Xavier Jirau-Serrano, BS, Carmine F Palermo, BS, Luigi Scotto, PhD, Kenneth P Olive, PhD, Govind Bhagat, MD, Serge Cremers, PhD, Jennifer E Amengual, MD, Owen A. O'Connor, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 2758.
https://doi.org/10.1182/blood.V120.21.2758.2758
Published: 2012